Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06533826 · ClinicalTrials.gov registry record · Phase 2
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
A Phase 2 study of Breast Cancer and Metastatic Breast Cancer, sponsored by Ana C Garrido-Castro, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 357
- Enrollment target
- 11
- Study locations
NCT06533826: Recruiting Phase 2 study of Breast Cancer and Metastatic Breast Cancer, sponsored by Ana C Garrido-Castro, MD.
NCT06533826 is a Phase 2 study of Breast Cancer and Metastatic Breast Cancer that is actively recruiting participants, run by Ana C Garrido-Castro, MD. The registered enrollment target is 357 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (87% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06533826, a Phase 2 study of Breast Cancer and Metastatic Breast Cancer, is actively recruiting participants, sponsored by Ana C Garrido-Castro, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 357 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HER2-low or HER2-0) metastatic breast cancer. The names of the study drugs involved in this study are: * Datopotamab deruxtecan (a type of antibody drug conjugate) * Trastuzumab deruxtecan (a type of antibody drug conjugate)
Primary Outcome
Objective response rate (ORR), defined as best overall response of either complete or partial response, will be assessed among participants who start protocol therapy and have measurable disease at screening. Radiographic response will be assessed using RECIST 1.1 criteria as defined per protocol.
Conditions Studied
Interventions
- DRUG Datopotamab Deruxtecan
- DRUG Trastuzumab Deruxtecan
Study Locations (11)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Alabama
- University of Alabama - Birmingham
California
- University of San Francisco - San Francisco
Connecticut
- Yale University Cancer Center - New Haven
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Illinois
- University of Chicago Medical Center - Chicago
New York
- Montefiore Einstein Comprehensive Cancer Center - The Bronx
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2038-08-01 |
| Phase | Phase 2 |
What NCT06533826 shows while recruiting
NCT06533826 is an interventional study that assigns participants to a tested intervention. The registered 357 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (87% lower).
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Datopotamab Deruxtecan is the first listed.
NCT06533826 lists 11 locations in 10 states (Massachusetts, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT06533826 about?
NCT06533826 is a clinical study titled "TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd". The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HER...
What is the current status of trial NCT06533826?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 357 participants. The study started on 2024-10-29. Estimated completion is 2038-08-01.
What conditions does trial NCT06533826 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic Breast Cancer, HER2-Negative Breast Cancer, HER2 Low Breast Cancer.
What interventions are being tested in trial NCT06533826?
The interventions under investigation include: Datopotamab Deruxtecan (DRUG), Trastuzumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT06533826?
This trial is sponsored by Ana C Garrido-Castro, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06533826 being conducted?
This trial has 11 study locations across Alabama, California, Connecticut, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06533826's enrollment target sits among peer trials
357 254th of 1224 higher than 970 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062888 · 357 participants · Phase 2
FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial
- NCT06109766 · 357 participants · NA
Delivering Evidence-Based Parenting Services to Families in Child Welfare Using Telehealth
- NCT06231342 · 357 participants · NA
Endotracheal Tube (ETT) 180: Stylet-loaded Endotracheal Tube Rotation Before Insertion
- NCT06679621 · 357 participants · NA
A Telehealth Intervention to Increase Patient Preparedness for Surgery in Latinas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI